{"nctId":"NCT02260791","briefTitle":"A Study to Compare FKB327 Efficacy and Safety With Humira速 in Rheumatoid Arthritis Patients","startDateStruct":{"date":"2014-12"},"conditions":["Arthritis, Rheumatoid"],"count":728,"armGroups":[{"label":"FKB327","type":"EXPERIMENTAL","interventionNames":["Drug: FKB327"]},{"label":"Humira速","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Humira速"]}],"interventions":[{"name":"FKB327","otherNames":[]},{"name":"Humira速","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female aged 18 years or over\n2. Patients have been diagnosed with Rheumatoid Arthritis (RA) for at least 3 months\n3. Patient has active RA\n4. Patient has taken a stable dose of methotrexate for at least 3 months\n\nExclusion Criteria:\n\n1. Patient has been previously treated with adalimumab\n2. Patient has been previously treated or has ongoing treatment with prohibited medications\n3. Patient has been immunised with a live or attenuated vaccine in past 4 weeks\n4. Patient has positive result for HIV, HBV, HCV or TB infection\n\nOther Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"American College of Rheumatology (ACR) 20 Response Rate","description":"The primary efficacy endpoint was the ACR20 response rate at Week 24.\n\nAn ACR20 response meant that the patient achieved a 20% improvement in Tender Joint Count and Swollen Joint Count and in at least 3 of the other 5 Core Data Set elements listed below.\n\n* Acute phase reactant (CRP)\n* Patient global assessment of disease activity\n* Physician global assessment of disease activity\n* Patient pain scale\n* Disability/functional questionnaire (patient completed Health Assessment Questionnaire Disability Index \\[HAQ-DI\\])","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","spread":null},{"groupId":"OG001","value":"74.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Activity Score 28 (DAS28) Based on C-reactive Protein (DAS28-CRP) Score","description":"The DAS28-CRP assessment involved evaluating the number of tender (TJC) and swollen (SJC) joints (out of 28 specified joints), serum CRP, and patient global assessment of disease activity (VAS from 0 to 100, very well to extremely bad). The DAS28-CRP is a number on a scale from 0 to 10 indicating the current activity of the patient's RA. A higher score indicates higher disease activity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.05","spread":"0.913"},{"groupId":"OG001","value":"6.06","spread":"0.852"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.92","spread":"1.070"},{"groupId":"OG001","value":"4.86","spread":"1.203"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.44","spread":"1.317"},{"groupId":"OG001","value":"4.43","spread":"1.383"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.11","spread":"1.295"},{"groupId":"OG001","value":"4.09","spread":"1.397"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.81","spread":"1.320"},{"groupId":"OG001","value":"3.85","spread":"1.339"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.68","spread":"1.304"},{"groupId":"OG001","value":"3.67","spread":"1.419"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.58","spread":"1.329"},{"groupId":"OG001","value":"3.57","spread":"1.388"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.47","spread":"1.298"},{"groupId":"OG001","value":"3.47","spread":"1.336"}]}]}]},{"type":"SECONDARY","title":"ACR20 Response Rates Over Time","description":"An ACR20 response meant that the patient achieved a 20% improvement in Tender Joint Count and Swollen Joint Count and in at least 3 of the other 5 Core Data Set elements listed below.\n\n* Acute phase reactant (CRP)\n* Patient global assessment of disease activity\n* Physician global assessment of disease activity\n* Patient pain scale\n* Disability/functional questionnaire (patient completed Health Assessment Questionnaire Disability Index \\[HAQ-DI\\])","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.3","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"52.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.6","spread":null},{"groupId":"OG001","value":"67.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null},{"groupId":"OG001","value":"72.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.6","spread":null},{"groupId":"OG001","value":"74.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"77.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.1","spread":null},{"groupId":"OG001","value":"79.3","spread":null}]}]}]},{"type":"SECONDARY","title":"ACR50 Response Rates Over Time","description":"An ACR50 response meant that the patient achieved a 50% improvement in Tender Joint Count and Swollen Joint Count and in at least 3 of the other 5 Core Data Set elements listed below.\n\n* Acute phase reactant (CRP)\n* Patient global assessment of disease activity\n* Physician global assessment of disease activity\n* Patient pain scale\n* Disability/functional questionnaire (patient completed Health AssessmentQuestionnaire Disability Index \\[HAQ-DI\\])","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null},{"groupId":"OG001","value":"17.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":null},{"groupId":"OG001","value":"30.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","spread":null},{"groupId":"OG001","value":"35.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","spread":null},{"groupId":"OG001","value":"44.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"49.4","spread":null}]}]}]},{"type":"SECONDARY","title":"ACR70 Response Rates Over Time","description":"An ACR70 response meant that the patient achieved a 70% improvement in Tender Joint Count and Swollen Joint Count and in at least 3 of the other 5 Core Data Set elements listed below.\n\n* Acute phase reactant (CRP)\n* Patient global assessment of disease activity\n* Physician global assessment of disease activity\n* Patient pain scale\n* Disability/functional questionnaire (patient completed Health AssessmentQuestionnaire Disability Index \\[HAQ-DI\\])","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null},{"groupId":"OG001","value":"6.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"10.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":null},{"groupId":"OG001","value":"13.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":null},{"groupId":"OG001","value":"23.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":null},{"groupId":"OG001","value":"25.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Swollen Joint Count","description":"Counts of swollen joints from amongst 66 selected joints performed by a trained and qualified joint assessor using standardised techniques recommended by the European League Against Rheumatism (EULAR). Joints were classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66 with higher scores indicating severe disease. Swollen joint count is a value of the individual ACR core set variables.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":"9.1"},{"groupId":"OG001","value":"16","spread":"8.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"6.04"},{"groupId":"OG001","value":"3.5","spread":"5.23"}]}]}]},{"type":"SECONDARY","title":"Tender Joint Count","description":"Counts of tender joints from amongst 68 selected joints were performed by a trained and qualified joint assessor using standardised techniques recommended by the European League Against Rheumatism (EULAR). Joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68 with higher scores indicating severe disease.Tender joint count is a value of the individual ACR core set variables.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":"14.49"},{"groupId":"OG001","value":"25.9","spread":"14.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"10.56"},{"groupId":"OG001","value":"8.1","spread":"9.36"}]}]}]},{"type":"SECONDARY","title":"Analysis of Serum C-Reactive Protein (CRP) Concentration","description":"Analysis of serum C-Reactive Protein (CRP) concentrations for inclusion in the ACR20/50/70 and DAS28-CRP scores was performed by a central laboratory. Elevation of CRP is a nonspecific marker of inflammation. Values above 10 mg/L were considered to be abnormally high. Decrease in level of CRP indicates reduction in inflammation.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.12","spread":"26.746"},{"groupId":"OG001","value":"26.73","spread":"28.534"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.98","spread":"16.819"},{"groupId":"OG001","value":"11.78","spread":"18.528"}]}]}]},{"type":"SECONDARY","title":"Patient Assessment of Disease Activity","description":"Patient assessment of disease activity visual analogue scale (VAS) will be assessed on 100-point scales (ranging from very well (0) to extremely bad (100)).The patient assessment of disease activity VAS will contribute to the calculation of the DAS28 score. The patient assessment of disease activity VAS will contribute to the calculation of ACR20, ACR50 and ACR70 response.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":"17.98"},{"groupId":"OG001","value":"68.2","spread":"18.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.2","spread":"24.04"},{"groupId":"OG001","value":"33.2","spread":"23.4"}]}]}]},{"type":"SECONDARY","title":"Physician Assessment of Disease Activity","description":"Physician assessment of disease activity visual analogue scale (VAS) will be assessed on 100-point scale (ranging from very low (0) to very high (100)). The physician assessment of disease activity VAS will contribute to the calculation of ACR20, ACR50 and ACR70 response.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","spread":"14.58"},{"groupId":"OG001","value":"66.2","spread":"15.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":"17.29"},{"groupId":"OG001","value":"21.5","spread":"16.97"}]}]}]},{"type":"SECONDARY","title":"Patient's Assessment of Pain","description":"An injection site pain visual analogue score (VAS) will be administered to the patient. To determine the extent of the pain, patients will be asked to place a small vertical mark on a horizontal scale from 0 to 100, the ends of which are labelled with the extreme responses to be measured (\"No pain\" at 0 and \"Intolerable pain\" at 100). Patient's assessment of pain is a value of the individual ACR core set variables.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.8","spread":"18.71"},{"groupId":"OG001","value":"67.7","spread":"18.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":"23.86"},{"groupId":"OG001","value":"33.6","spread":"23.86"}]}]}]},{"type":"SECONDARY","title":"Health Assessment Questionnaire Disability Index (HAQ-DI)","description":"The HAQ-DI is a 20-question, self-administered instrument that measures the patient's functional ability on a 4-level difficulty scale (0 to 3, with 0 representing normal or no difficulty and 3 representing inability to perform). Eight categories of functioning are included: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. This scale is sensitive to change and is a good predictor of future disability. HAQ-DI is a value of the individual ACR core set variables.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.78","spread":"0.544"},{"groupId":"OG001","value":"1.8","spread":"0.538"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":"0.696"},{"groupId":"OG001","value":"1.26","spread":"0.719"}]}]}]},{"type":"SECONDARY","title":"DAS28-CRP Score Over Time","description":"The DAS28 score is a combined index that has been developed to measure the disease activity in patients with RA and has been extensively validated for its use in clinical studies. The DAS28-CRP assessment involved evaluating the number of tender (TJC) and swollen (SJC) joints (out of 28 specified joints), serum CRP, and patient global assessment of disease activity (VAS from 0 to 100, very well to extremely bad). The individual results are summed using a formula. The DAS28 is a number on a scale from 0 to 10 indicating the current activity of the patient's RA. A higher score indicates higher disease activity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.05","spread":"0.913"},{"groupId":"OG001","value":"6.06","spread":"0.852"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.47","spread":"1.298"},{"groupId":"OG001","value":"3.47","spread":"1.336"}]}]}]},{"type":"SECONDARY","title":"DAS28 Score Based on Erythrocyte Sedimentation Rate (DAS28-ESR)","description":"The DAS28 score is a combined index that has been developed to measure the disease activity in patients with RA and has been extensively validated for its use in clinical studies. The DAS28-ESR assessment involved evaluating the number of tender (TJC) and swollen (SJC) joints (out of 28 specified joints), serum ESR, and patient global assessment of disease activity (VAS from 0 to 100, very well to extremely bad). The individual results are summed using a formula. The DAS28 is a number on a scale from 0 to 10 indicating the current activity of the patient's RA. A higher score indicates higher disease activity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.52","spread":"0.941"},{"groupId":"OG001","value":"6.56","spread":"0.902"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.24","spread":"1.382"},{"groupId":"OG001","value":"4.24","spread":"1.353"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.82","spread":"1.384"},{"groupId":"OG001","value":"3.85","spread":"1.371"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Patients Developing Anti-drug Antibodies (ADAs)","description":"Blood samples for the assessment of ADA activity were collected at Baseline (Week 0), prior to dosing at Weeks 2, 4, 12, and 24.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.4","spread":null},{"groupId":"OG001","value":"94.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.7","spread":null},{"groupId":"OG001","value":"59.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.3","spread":null},{"groupId":"OG001","value":"40.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Trough Adalimumab Concentration","description":"Blood samples for the quantification of adalimumab concentration in serum were collected at Baseline (Week 0), prior to dosing at Weeks 2, 4, 12 and 20, and Week 24. Samples were taken prior to dosing (trough samples).","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2434.6","spread":null},{"groupId":"OG001","value":"2089.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3450.6","spread":null},{"groupId":"OG001","value":"2932.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4316.3","spread":null},{"groupId":"OG001","value":"3851.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4369.8","spread":null},{"groupId":"OG001","value":"3873","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4126","spread":null},{"groupId":"OG001","value":"3758.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":366},"commonTop":["Nasopharyngitis"]}}}